Why kid-friendly medications can be expensive for parents | PBS NewsHour
When prescribing medications, caring for children poses a particular challenge. They’re not just little adults. Their still-developing brains and bodies metabolize drugs differently, and what works for grown-ups can yield radically different — and sometimes dangerous — results in kids. And now, even as high drug prices make headlines, the challenge of getting sick children the kind of medication they can take and tolerate — often by creating liquid formulations of drugs that are already on the market — is seen by some companies as a lucrative opportunity. It is part of a pattern in which patent laws and government incentives — meant to encourage development of less-profitable drugs — enable some companies to get a leg up in the market and set high prices. The Best Pharmaceuticals for Children Act, for instance, allows for delaying the approval of competing generics if companies test their drugs in children. And the Pediatric Research Equity Act requires more companies to have pediatric
Full Episode Wednesday, Jul 22
Explore this link on the map →related reading
- The pharma industry from Paul Janssen to today: why drugs got harder to develop and what we can do about it | Alex’s blogatelfo.github.io
- Why are our medicines so expensive? Spoiler: Not for the reasons you are being told… - PMCncbi.nlm.nih.gov
- Reverse Voxsplaining: Brand-Name Drugs | Slate Star Codexslatestarcodex.com
- Joe Biden Lowered Drug Prices. Does Anyone Care? - The Atlantictheatlantic.com
- Pharma Virumque | Slate Star Codexslatestarcodex.com
- Inside the Mafia of Pharma Pricing - BIG by Matt Stollerthebignewsletter.com
- Why fixing the IRA matters to all of us - RApportrapport.bio
- The Ozempocalypse Is Nigh - by Scott Alexanderastralcodexten.com
- How PBMs can use private-labelled drug products as a great escape from anti-steering policies - 46brooklyn Research46brooklyn.com
- Understanding Drug Pricing from Divergent Perspectives: State of Washington Prescription Drug Pricing Analysis - 3 ∆XIS Advisors3axisadvisors.com
- Why the FDA Is Slow to Remove Drugspress.asimov.com
- Eroom's law - Wikipediaen.wikipedia.org